GeoVax Labs, Inc. New - GOVX STOCK NEWS

GeoVax Labs, Inc. (GOVX) reported significant updates in their Q1 2021 financial results, including a net loss of $1.56 million, a 163% increase from Q1 2020. Cash reserves improved to $20.8 million, bolstered by a $10.3 million stock offering and $3.2 million from warrant exercises. The company is advancing its COVID-19 vaccine, supported by a $3.2 million NIH grant, focusing on a universal vaccine to counter multiple variants. GeoVax's patent portfolio expanded to over 70 applications, enhancing its position in COVID-19 and cancer immunotherapy.

GeoVax Labs, Inc (NasdaqCM: GOVX) announced that Chairman & CEO David Dodd will participate in the Benzinga Global Small Cap Conference on May 13-14, 2021. Dodd will deliver a corporate presentation at 9:50am ET and join a panel discussion titled “Investing Post COVID – Back to the Fundamentals” at 11:50am ET on May 13. The panel will focus on healthcare investing in a post-COVID environment. Investors can also request one-on-one meetings with Dodd after the conference.

GeoVax Labs, Inc. (NASDAQ: GOVX) will report its first quarter 2021 financial results on May 6, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, aimed at discussing financial results and company updates. The call will include a Q&A session. GeoVax is a clinical-stage biotechnology firm specializing in vaccines for infectious diseases and cancer, using a patented MVA-VLP platform. Their current developments include vaccines for COVID-19, HIV, Zika Virus, and various cancers.

GeoVax Labs (NasdaqCM: GOVX) announced a Notice of Allowance for a patent on methods to generate an immune response to Hepatitis B Virus (HBV), a critical unmet medical need affecting over 250 million people globally. The patent is co-owned with Georgia State University, emphasizing collaboration in combating chronic HBV infections. While the company's main focus remains on COVID-19 vaccines and cancer therapies, the development of an HBV treatment is part of its long-term strategy. This patent adds to GeoVax's growing portfolio of over 70 patents.

GeoVax Labs, Inc. (GOVX, GOVXW) reported its 2020 financial results, showing a net loss of $3.0 million, up from $2.4 million in 2019. Grant revenues increased from $1.2 million to $1.8 million, primarily due to U.S. Department of Defense support for the Lassa Fever vaccine. As of December 31, 2020, cash balances rose significantly to $9.9 million, compared to $283,341 in 2019, supported by a $11.2 million public offering. The company is advancing its COVID-19 vaccine and immuno-oncology programs, with several data announcements expected in the first half of 2021.

GeoVax Labs (NasdaqCM: GOVX) announces participation in the Benzinga Biotech Small Cap Conference on March 24-25, 2021. CEO David Dodd will present an overview of the company’s immunotherapy and vaccine R&D, focusing on its COVID-19 vaccine targeting various SARS-CoV-2 variants. Chief Scientific Officer Mark Newman, PhD, will join a panel on advancements in cancer immunotherapies. Investors can view the presentations by registering for the conference and can request one-on-one meetings with Dodd.

GeoVax Labs, Inc. (GOVX) has scheduled its 2020 financial results release for March 23, 2021, after market close. A conference call will follow on March 24, 2021, at 8:00 a.m. ET, to discuss these results and corporate updates. The company specializes in human immunotherapies and vaccines targeting infectious diseases and cancer, utilizing its proprietary Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform. Upcoming developments include preventive vaccines for COVID-19, HIV, and other diseases, with potential human clinical trials managed with the National Institutes of Health.

GeoVax Labs, Inc. (GOVX) is set to present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The company’s Chairman and CEO, David Dodd, will discuss ongoing research in COVID-19 and cancer immunotherapy. Additionally, Mark Newman, PhD, Chief Scientific Officer, will join a panel on cancer vaccines and immuno-oncology. Investors can register for the conference to view presentations and schedule one-on-one meetings with Dodd.

GeoVax Labs announces the filing of two key patent applications focused on vaccines for SARS-CoV-2 and cancer immunotherapies. The International Patent Application under the Patent Cooperation Treaty aims to protect their COVID-19 vaccines, which target multiple viral antigens, potentially reducing susceptibility to mutations. Additionally, a U.S. patent application was filed to enhance immune responses to cancer through its modified vaccinia Ankara viral vector technology. The company now has over 70 patent applications and is advancing towards clinical development in both areas.